NVS — NOVARTIS AG catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

14 verified catalyst event(s) for NOVARTIS AG (ticker NVS). Each is linked to its official source. Verified as of 2026-06-22.

Next verified catalyst

2026-06-30 — Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiov · official source ↗

Upcoming

Date	Event	Company	Drug	Official source & verification
2026-06-30 in 8d ESTIMATED	READOUT Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Maj Phase 3 · Cardiovascular Disease and Lipoprotein(a)	NVS NOVARTIS AG	TQJ230	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Study of 177Lu-FAP-2286 in Advanced Solid Tumors Phase 1/2 · Solid Tumor	NVS NOVARTIS AG	68Ga-FAP-2286, 177Lu-FAP-2286	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-23 in 1mo ESTIMATED	READOUT Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants Wi Phase 3 · Relapsing Multiple Sclerosis	NVS NOVARTIS AG	Remibrutinib, Teriflunomide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-23 in 1mo ESTIMATED	READOUT Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants Wi Phase 3 · Relapsing Multiple Sclerosis	NVS NOVARTIS AG	Remibrutinib, Teriflunomide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-25 in 2mo ESTIMATED	READOUT Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanc Phase 3 · Non-Small Cell Lung Cancer	NVS NOVARTIS AG	JDQ443, docetaxel	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-09-21 in 3mo ESTIMATED	READOUT A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Phase 2 · Amyotrophic Lateral Sclerosis (ALS)	NVS NOVARTIS AG	VHB937	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-09-24 in 3mo ESTIMATED	READOUT An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 Phase 1/2 · Systemic Lupus Erythematosus, Lupus Nephritis	NVS NOVARTIS AG	YTB323	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-09-30 in 3mo ESTIMATED	READOUT Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Phase 1/2 · KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung	NVS NOVARTIS AG	JDQ443, trametinib, Ribociclib, cetuxima	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-10-01 in 3mo ESTIMATED	READOUT A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular De Phase 2 · Age-Related Macular Degeneration	NVS NOVARTIS AG	Iptacopan (LNP023)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-10-15 in 4mo ESTIMATED	READOUT An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combin Phase 2 · Metastatic Castration Resistant Prostate Cancer (mCRPC)	NVS NOVARTIS AG	AAA617, ARPI: Abiraterone, ARPI: Enzalut	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-10-26 in 4mo ESTIMATED	READOUT Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Additio Phase 3 · Coronary Artery Disease	NVS NOVARTIS AG	Inclisiran sodium 300 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-10-29 in 4mo ESTIMATED	READOUT Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in P Phase 3 · Primary Immune Thrombocytopenia (ITP)	NVS NOVARTIS AG	Ianalumab, Corticosteroids	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-11-05 in 5mo ESTIMATED	READOUT Pediatric Long-Term Follow-up and Rollover Study Phase 4 · Diffuse Astrocytoma, Anaplastic Astrocytoma	NVS NOVARTIS AG	dabrafenib, trametinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-11-06 in 5mo ESTIMATED	READOUT 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, Phase 3 · Chronic Spontaneous Urticaria	NVS NOVARTIS AG	LOU064 (blinded)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change